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osting by EAbstract Background/aim: Hepatitis C virus (HCV) infection is a worldwide health issue with
about 3% of the world’s population having HCV. In Saudi Arabia, prevalence ranges from
1.0% to 5.87%. Cutaneous diseases can indicate the presence of HCV infection.
Objectives: The research project aims to identify prospectively the prevalence of HCV infection
in 200 patients with various types of skin disorders and 50 healthy blood donors, and to quantify
this association through clinical and laboratory investigations.
Methods: Two hundred patients with cutaneous manifestations who presented at the Dermatol-
ogy outpatient clinics of King Khalid University Hospital (KKUH) and King Abdulaziz University
Hospital (KAUH), Riyadh, and 50 healthy blood donors were prospectively studied. Patients were
examined by a team of dermatologists and clinical data were collected through a standard question-
naire. Ten milliliters of venous blood were collected from fully consented, 8–10 h fasting patients
and serum was analyzed for AST, ALT, double infection with HBsAg, anti-HCV antibodies, and
screened for HCV-RNA-PCR.
Results: Patients from the study (n= 200) consisted of 25 (12.5%) males and 175 (87.5%)
females, with a mean age of 42.9 ± 15.06 years. Clinical examinations revealed that (35%) had urti-
caria, followed by pruritus (28%), lichen planus (25.5%), prurigo (10%), and palpable purpura
(1.5%). The main serum levels of ALT and AST were within the normal reference ranges.
Twenty-four patients (12%) tested positive for anti-HCV antibodies, with 15 (62.5%) being positive
for the presence of HCV-RNA by PCR and 9 (37.5%) resulting negative for the viral RNA. Of thecom (M. Halawani).
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36 M. Halawani et al.24 anti-HCV positive patients, pruritus 12 (50%), urticaria 5 (20.8%), lichen planus 5(20.8%), and
palpable purpura 2(8.3%). Five (2.5%) patients were positive for HBsAg, with 3 (60%) having
pruritus and 2 (40%) presenting with urticaria. Of the 50 healthy blood donors, only one (2%)
tested positive for the presence of anti-HCV antibodies, and all the donors tested negative for
HBsAg.
Conclusion: Results clearly indicate the prevalence of anti-HCV antibodies in 24 out of 200
patients (12%) with skin manifestations seen at the dermatology outpatient clinics and documented
with HCV-RNA-PCR positivity of 15/24 (62.5%). A p-value of <0.05 was considered signiﬁcant,
therefore, it is suggested that patients presenting with urticaria, pruritus and LP be investigated to
exclude the possibility of HCV infection.
ª 2009 King Saud University. All rights reserved.1. Introduction
Many reports have shown that cutaneous manifestations are
often the ﬁrst signs of chronic HCV infection and these are indi-
cated in 20–40% of the patients presenting to the dermatology
clinics, therefore dermatologists must be aware of skin disor-
ders associated with viral infection Schwartz and Birnkrant,
2008; Galossi et al., 2007. The most commonly encountered
dermatological manifestations of HCV infection includes
mixed cryoglo-bulinemia (MC), porphyria cutanea tarda
(PCT), cutaneous and/or oral lichen planus (LP), urticaria,
pruritus, thrombocytopenic purpura and cutaneous vasculitis
(Schwartz and Birnkrant, 2008; Galossi et al., 2007; Poljacki
et al., 2000; Cordel et al., 2000). Although majority of skin
manifestations of chronic HCV infection represent the clinical
impression of autoimmune phenomena, however, precise path-
ogenesis of these extra-hepatic complications is not well under-
stood (Pyropoulos and Reddy, 2001; Dega et al., 1998).
The most documented extra-hepatic manifestation of HCV
infection is MC, and is reported in about half of all the HCV
patients (Schott et al., 2001). Chronic HCV infection has also
been associated with PCT (Bulaj et al., 2000). Similarly, the
presence of increased frequency of HCV among LP patients
has put LP as one of the primary skin disorders associated with
the chronic HCV infection (Nagao et al., 2000; Arrieta et al.,
2000; Mignogna et al., 2000). Pruritus is also implicated in ad-
vanced chronic HCV infection and has been documented in
5–15% of patients, with chronic HCV infection (Dega et al.,
1998). There have been conﬂicting reports both in favor of
and against HCV-causing urticaria (Llanos et al., 1998).
This study was conducted to estimate the prevalence of
HCV exposure in skin disease patients and analyze the fre-
quency of HCV infection in patients with skin disease.
2. Methods
Demographic (age, sex, nationality, marital status) and clinical
data (symptoms, sign, past-medical history and predisposing
risk factors for HBV and HCV infection, types of skin disease
and its duration) of skin disease patients presenting with pru-
ritus, prurigo, urticaria and/or LP and healthy blood donors
(n= 50) were collected through a standardized questionnaire
conducted and examined by consultant dermatologists at King
Khalid University Hospital (KKUH) and King Abdulaziz
University Hospital (KAUH), Riyadh, Saudi Arabia. Ten
milliliters of whole blood were collected from healthy blood
donors and 8–10 h fasting skin disease patients, after consent.Sera were separated by centrifugation at 2500 rpm for 15 min
at 4 C, transferred in 1 mL quantities to four properly labeled
containers, and stored immediately at 70 C until the labora-
tory testing was performed for AST, ALT and HCV/HBV
serology at KKUH laboratories.
According to the manufacturer standard proto-cols, the fol-
lowing laboratory tests were done. Serum ALT and AST were
determined using Automated Multi-Channel Clinical Chemis-
try Analyzer. Anti-HCV antibodies were detected using Ortho
HCV 3.0 ELISA Test System (Ortho-clinical Diagnostics, Inc.,
UK). Anti-HCV positive samples were conﬁrmed by LIA (Lia
Tek HCV III, Organon Teknika, Germany). Commercially
available ELISA kits (Hepanostika HBsAg Uni-Form II Mic-
roelisa system; Biomerieux bv, Boseind 15, Netherlands) were
used for the determination of HBsAg in patient’s and healthy
blood donors, and anti-HCV positive sera were analyzed using
COBAS AMPLI-COR HCV ASSAY (Version 2-Roche Diag-
nostic Systems, Germany).
Results of 200 skin disease patients and 50 healthy blood
donors were analyzed using Statistical Package for Social Sci-
ences (SPSS) version 11.5 and are reported as mean ± stan-
dard deviation. Student’s t-test (two-tailed) was used to
examine the signiﬁcance of difference between the two sets of
data, and a p-value of <0.05 was considered signiﬁcant.3. Results
A total of 200 skin disease patients, consisting of 25 (12.5%)
males and 175 (87.5%) females with a mean age of 42.9 ± 15.1
years (range: 8–80 years) was studied (Table 1). The highest
prevalence of HCV and HBV risk factors among skin disease
patients was the history of intramuscular injection (Table 2).
Among the various types of skin manifestations, urticaria
was the most prevalent at 35% (n= 70) followed by pruritus
(28%), LP (25.5%) and prurigo (10%). Palpable purpura
was reported in three patients (1.5%) as seen in Tables 2 and 3.
The prevalence of anti-HCV, HBsAg and HCV-RNA-PCR
positivity is shown in Table 3. Among 51 patients with LP, 5
(9.8%) were anti-HCV positive, of which 2 (40%) were
HCV-RNA-PCR positive, none of which turned out positive
for HBsAg. Of 56 patients with pruritus, 12 (21.4%) were
anti-HCV positive of which 9 (75%) were HCV-RNA-PCR
positive and 3 (5.4%) were HBsAg positive. Among 70
patients with urticaria, 5 (7.1%) were anti-HCV positive of
which 3 (60%) were HCV-RNA-PCR positive and 2 (2.9%)
were positive for HBsAg. Of 20 patients with prurigo, two
were anti-HCV and HCV-RNA-PCR positive, and none were
Table 1 Demographic data of skin disease patients and healthy controls.
Skin Disease Patients Healthy controls
No. of patients 200 50
Males 25 (12.5%) 44 (88%)
Females 175 (87.5%) 6 (12%)
Age in years (mean ± SD) 42.9 ± 15.1 (range: 8–80 years) 25.5 ± 7.4 (range: 18–41 years)
Anti-HCV positive 24 (12%) 1 (2%)
Anti-HBsAg positive 5 (2.5%) 0
Table 2 Prevalence of HCV and HBV risk factors among skin disease patients (n= 200).
Parameters No. (%) L. planus Pruritus Urticaria Prurigo Palpable purpura
Total number of patients 200 51 (25.5) 56 (28) 70 (35) 20 (10) 3 (1.5)
Jaundice 11 (5.5) 2 (3.9) 6 (10.7) 2 (2.9) 1 (5) 0
Contact with jaundiced patient 10 (5) 2 (3.9) 4 (7.2) 3 (4.3) 1 (5) 0
Blood transfusion 33 (16.5) 7 (13.7) 12 (21.4) 10 (14.3) 3 (15) 1 (33.3)
Use of blood products 2 (1) 0 1 (1.8) 1 (1.4) 0 0
History of intramuscular injection 36 (18) 7 (13.7) 9 (16.1) 15 (21.4) 2 (10) 3 (100)
History of drug abuse 0 0 0 0 0 0
Sexual contact with HCV/HBV patient 10 (5) 2 (3.9) 4 (7.2) 3 (4.3) 1 (5) 0
Contact with HCV/HBV family member 15 (7.5) 5 (9.8) 3 (5.4) 5 (7.2) 2 (10) 0
Table 3 HBV and HCV in skin disease patients.
HCV parameters No. (%) L. planus Pruritus Urticaria Prurigo Palpable purpura
Total number of patients 200 51 (25.5) 56 (28) 70 (35) 20 (10) 3 (1.5)
HBsAg positive 5 (2.5) 0 3 (5.4) 2 (2.9) 0 0
HCV antibody negative 171 (85.5) 46 (90.2) 41 (73.2) 63 (90) 20 (100) 1 (33.3)
HCV antibody positive 24 (12) 5 (9.8) 12 (21.4) 5 (7.1) 2 (10)a 2 (66.7)
HCV-RNA-PCR positive 15 (62.5) 2 (40) 9 (75) 3 (60) 2 (10) 1 (50)
HCV-RNA-PCR negative 9 (37.5) 3 (60) 3 (25) 2 (40) 0 1 (50)
a Patients having prurigo with L. planus and palpable purpura.
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(66.7%) were anti-HCV positive of which 1 (50%) were
HCV-RNA-PCR positive and none were HBsAg positive
(Table 3). All of the 24 anti-HCV positive skin disease patients
were subjected to HCV-RNA-PCR screening employing stan-
dard protocols and molecular biology techniques. Of those 24
patients, 15 (62.5%) tested positive for the presence of viral
RNA by PCR screening, whereas 9 (37.5) were HCV-RNA-
PCR negative (Table 3).
The association between various types of skin manifesta-
tions and anti-HCV positive skin disease patients’ AST and
ALT values with the exception of LP (n= 5) and prurigo
(n= 2), patients who had pruritus (n= 12), urticaria
(n= 5), and palpable purpura (n= 2), had their mean serum
ALT activity within the normal reference ranges (20–65 U/L).
Although the number of patients were very limited, however,
both LP (n= 5; 80.80 ± 8.58; 71–95 U/L) and prurigo
(n= 2; 79 ± 2; 77–81 U/L) were associated with higher ALT
activity as compared to pruritus (48.38 ± 22.77; 17–84 U/L;
p= 0.008), urticaria (31.8 ± 16.48; 16–58 U/L; p= 0.004),
and palpable purpura (53.5 ± 23.5; 30–77 U/L; p= 0.037).
Unlike the ALT, the mean serum AST concentration among
our anti-HCV positive skin disease patients was slightly ele-vated above the normal range in all the categories of patients
including prurigo (65.5 ± 0.50; 65–66 U/L), LP (52.2 ±
22.23; 36–66 U/L), pruritus (46.5 ± 13.97; 24–73 U/L), and
palpable purpura (42 ± 23; 19–65 U/L), except urticaria where
AST was within the normal reference number range (26.67 ±
9.69; 15–40 U/L).
In addition to the 200 skin disease patients, 50 healthy
blood donors were also studied as ‘‘healthy controls’’ for the
validation of research methodology and laboratory protocols.
These blood donors were recruited through blood banks at
KKUH, Riyadh, and were examined by consultant dermatol-
ogists. Their demographic/clinical data and blood samples
were collected and analyzed. These blood donors consisted
of 44 (88%) male and 6 (12%) female with a mean age of
25.5 ± 7.4 (range: 18–41 years). The majority were Saudi
(96%) and were married (76%). Their clinical examination
did not reveal any skin manifestations and none of them re-
ported past exposure to any of the HCV risk factors. One of
the 50 blood donors (2%) tested positive for the presence of
anti-HCV antibodies while all of the donors tested negative
for HBsAg. Anti-HCV positive blood donor’s sample was sub-
jected to HCV-RNA-PCR screening which tested negative for
the presence of HCV-RNA.
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Our results are in agreement with previous reports from Saudi
Arabia as well as other countries which indicate that persistent
exposure to HCV risk factors signiﬁcantly predisposes healthy
population to the risk of acquiring HCV infection (Bakir,
1992; Fakeeh and Zaki, 1999; Sandhu et al., 1999; Flamm
et al., 1998; Karkar, 2007; Sharara et al., 1996).
HBsAg was detected in only 5/200 (2.5%) whereas none of
the 200 skin disease patients tested positive for both HBV and
HCV. Despite the fact that HBV was more prevalent among
Saudi population than HCV, our results suggest that skin
manifestations of viral hepatitis may be associated more with
HCV than HBV among chronic hepatitis patients.
Of the total 200 studied patients, 24 (12%) tested positive
for anti-HCV antibodies, showing a signiﬁcantly higher preva-
lence than the existing prevalence of 0.1–6.9% among Saudi
population (Bakir, 1992; Madani, 2007; El-hazmi, 2004). Fifty
percent of our anti-HCV positive skin disease patients had
pruritus followed by LP (20.83%) urticaria (20.83%), palpable
purpura (8.3%) and prurigo (8.3%). Our results are not in
total agreement with many studies from Western countries
which have shown MC and PCT as the most predominant
extra-hepatic skin manifestations among chronic HCV patients
(Galossi et al., 2007; Sterling and Bralow, 2006). As 50% of
our pruritus patients were positive for anti-HCV antibodies,
therefore, it is suggested that such cases should be screened
for anti-HCV antibodies as well as HBsAg. Another study
showed that the most common skin disease among chronic
HCV patient was generalized pruritus (18.57%), followed by
LP (4.28%) Dervis and Serez, 2005. Similarly, Bonacini re-
ported that 20% of their chronic hepatitis C patients presented
with pruritus (Bonacini, 2000). Reports from France and
USA have also shown that pruritus has been documented in
5.0–15% of patients with chronic HCV infection (Cordel
et al., 2000; Jackson, 2002).
Several studies have shown that 15–35% of LP patients
have hepatic disorders Nagao et al., 2000. We found both
LP and urticaria present among anti-HCV positive skin disease
patients (20.83%). This is in agreement with the study done in
Saudi Arabia by Asaad and Samdani (2005) where 114 LP
patients (26.3%) tested positive for anti-HCV antibodies.
Five (20.83%) of our anti-HCV positive patients had urti-
caria showing a weaker association with HCV as compared
to pruritus (50%). Whether hepatitis C infection causes
urticaria or not is still a debatable issue and there have been
conﬂicting reports both in favor of and against HCV-causing
urticaria (Llanos et al., 1998). Several studies have suggested
that HCV status should be checked in patients presenting with
urticaria in areas with a high HCV prevalence (Paoletti et al.,
2002; Crowson et al., 2003).
Although 20 (10%) of our studied patients had prurigo,
none of them tested positive for anti-HCV antibodies except
two patients who already had LP and palpable purpura,
respectively. According to our ﬁndings, the association be-
tween HCV and prurigo is poor, as compared to both pruritus,
urticaria and LP. The relationship between chronic HCV infec-
tion and prurigo is not well documented. Poda´nyi et al. (2004)
described two chronic HCV patients with intense pruritis and
secondary prurigo. In our study three patients had palpable
purpura of which two tested positive for anti-HCV antibodies.Currently, there are no data available from Saudi Arabia
regarding the prevalence of palpable purpura in Saudi popula-
tion and its association with HCV.
Fifteen (62.5%) of our anti-HCV positive skin disease pa-
tients tested positive for the presence of viral RNA thereby
reﬂecting an active HCV replication (viremia) among these pa-
tients. On the contrary, only one of the healthy blood donors
tested positive for anti-HCV, however, it was negative for
HCV-RNA by PCR. The presence of statistically signiﬁcant
high prevalence of HCV-RNA in our studies skin disease pa-
tients is suggestive of an etiological role of HCV infection in
various types of skin manifestations.
In the present study, we could not ﬁnd a signiﬁcant differ-
ence in LFT markers between various categories of our studied
skin disease patients.References
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